UNITED STATES DISTRICT COURT

DISTRICT OF MASSACHUSETTS

ALBERT AFTOORA and AMJAD KHAN Individually and On Behalf of All Others Similarly Situated, and NADIA SHASH as Sole Managing Member of PolyCon Solutions LLC, individually, Plaintiffs, v. BIOGEN INC., MICHEL VOUNATSOS, and ALFRED W. SANDROCK, JR., Defendants.	**CASE No.: 1:21-cv-10479-IT**

NOTICE OF PENDENCY AND PROPOSED SETTLEMENT OF CLASS ACTION

If you purchased or otherwise acquired Biogen Inc. ("Biogen" or the "Company") common stock during the period from October 22, 2019 to November 5, 2020, both dates inclusive ("Class Period"), you could get a payment from a class action settlement (the "Settlement").

A federal court has authorized this Notice. This is not attorney advertising.

- If approved by the Court, the Settlement will provide twenty-five million dollars ($25,000,000) (the "Settlement Amount") gross, plus interest as it accrues, less attorneys' fees, costs, administrative expenses, and any taxes on interest, to pay claims of investors who purchased or otherwise acquired Biogen common stock during the Class Period. The Settlement will be divided as follows: 20% ($5 million) for purchases made in the period from October 22, 2019 through July 21, 2020 ("October 22, 2019 to July 21, 2020 Class Period," and "Dismissed Claims"); and 80% ($20 million) for purchases made in the period from July 22, 2020, through November 5, 2020 ("July 22, 2020 to November 5, 2020 Class Period," and "Active Claims").
- Based on Plaintiffs' damages consultant's estimates, the Settlement represents estimated average recoveries of: $1.12 per share for the approximately 17,887,982 shares traded during the July 22, 2020 to November 5, 2020 Class Period; and $0.19 per share for the approximately 26,836,300 shares traded during the October 22, 2019 to July 21, 2020 Class Period. This is not an estimate of the actual recovery per share you should expect. Your actual recovery, if any, will depend on the aggregate losses of all Settlement Class Members, the date(s) you purchased and sold Biogen common stock, the purchase and sale prices, and the total number and amount of claims filed.
- Lead Counsel will ask the Court to award attorneys' fees in an amount not to exceed one-third of the Settlement Amount ($8,333,333.33) plus interest, and reimbursement of no more than $1,900,000 in litigation expenses plus interest and reimbursement of Plaintiffs' costs and expenses related to their representation of the Settlement Class ("Plaintiffs' Expenses") in an aggregate amount not to exceed $45,000, for a total of $10,278,333.33 (costs and expenses of Counsel and Plaintiffs' Expenses are,

collectively, "Litigation Expenses"). Collectively, the attorneys' fees and Litigation Expenses are estimated not to exceed an average of $0.46 per share of Biogen common stock damaged during the July 22, 2020 to November 5, 2020 Class Period, and $0.08 per share of Biogen common stock damaged during the October 22, 2019 to July 21, 2020 Class Period. If approved by the Court, these amounts will be paid solely from the Settlement Fund.

- The average approximate recovery, after deduction of attorneys' fees and expenses approved by the Court, is $0.66 per share of Biogen common stock damaged during the July 22, 2020 to November 5, 2020 Class Period, and $0.11 per share of Biogen common stock damaged during the October 22, 2019 to July 21, 2020 Class Period. This estimate is based on the assumptions set forth in the preceding paragraphs. This is not an estimate of the actual recovery per share you should expect. Your actual recovery, if any, will depend on the aggregate losses of all Settlement Class Members, the date(s) you purchased and sold Biogen common stock, the purchase and sale prices, and the total number and amount of claims filed.
- The Settlement resolves the above-captioned action concerning whether Biogen, Michel Vounatsos, and Alfred W. Sandrock, Jr. (collectively, "Defendants") violated the federal securities laws by issuing false and misleading statements to investors. Defendants deny each and every claim and contention alleged and deny any misconduct or wrongdoing whatsoever.
- Your legal rights will be affected whether you act or do not act. If you do not act, you may permanently forfeit your right to any recovery. Therefore, you should read this Notice carefully.

YOUR LEGAL RIGHTS AND OPTIONS IN THIS SETTLEMENT	
Submit a Claim Form	Fill out the attached Proof of Claim and Release Form ("Claim Form") and submit it no later than **January 19, 2027**. **This is the only way to get a payment from the Settlement.**
Exclude Yourself from the Settlement Class	If you wish to exclude yourself from the Class, submit a request for exclusion no later than **January 19, 2027.** This is the only way you can ever be part of any other lawsuit against the Defendants or other Defendants' Releasees relating to the legal claims in this case. **If you exclude yourself, you will receive no payment and cannot object or speak at the hearing**.
Object	If you do not like the proposed Settlement, the proposed Plan of Allocation, and/or the request for attorneys' fees and reimbursement of Litigation Expenses, you may write to the Court no later than **February 12, 2027,** about why you do not like them. You can still submit a Claim Form. If the Court approves the Settlement, you will be bound by it.
Go to the Hearing	Filing a timely written objection and notice of intention to appear at least twenty-one (21) days before the hearing allows you to speak in Court about the fairness of the proposed Settlement, the proposed Plan of Allocation, and/or the request for attorneys' fees and reimbursement of Litigation Expenses at the hearing on **March 5, 2027 at 10:00 a.m. ET**. You can still submit a Claim Form. If the Court approves the Settlement, you will be bound by it.
Do Nothing	**Get no payment from the Settlement AND give up your right to bring your own individual action relating to the claims asserted in the Action.**

INQUIRIES

Please do not contact the Court regarding this Notice. All inquiries concerning this Notice, the Claim Form, or the Settlement should be directed to:

Claims Administrator		Lead Counsel
Biogen Inc. Securities Litigation c/o Strategic Claims Services P.O. Box 230 600 N. Jackson St., Ste. 205 Media, PA 19063 Tel.: (866) 274-4004 Fax: (610) 565-7985 info@strategicclaims.net	**or**	Jonathan Horne THE ROSEN LAW FIRM, P.A. 275 Madison Ave, 40th Floor New York, NY 10016 Tel: (212) 686-1060 Fax: (212) 202-3827 jhorne@rosenlegal.com

DEFINITIONS

All capitalized terms not otherwise defined herein shall have the same meanings as set forth in the Stipulation of Settlement, dated October 6, 2026, which is available on the website, www.strategicclaims.net/Biogen2019.

COMMON QUESTIONS AND ANSWERS CONCERNING THE SETTLEMENT

1. Why did I get this Notice?

You or someone in your family may have purchased or otherwise acquired Biogen common stock during the period from October 22, 2019 through November 5, 2020, both dates inclusive.

2. What is this lawsuit about?

The case is known as *Shash v. Biogen Inc., et al.*, Case No. 1:21-cv-10479-IT (the "Action"). The Court in charge of the Action is the United States District Court for the District of Massachusetts. The history of Action is set forth in Section I.A of the Stipulation.

On September 12, 2022, the Court granted Defendants' motion to dismiss the Second Amended Complaint. On October 11, 2023, the United States Court of Appeals for the First Circuit affirmed the dismissal of all claims except those based on a single statement, which it found sufficient to state a claim. As a result, only investors with Active Claims (July 22, 2020 through November 5, 2020) had claims that remained pending in the Action.

The Action involves allegations that Defendants violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934. Defendants have denied and continue to deny all allegations of wrongdoing, fault, liability, or damage whatsoever asserted in the Action. The Settlement shall in no event be construed as, or deemed to be evidence of, liability, fault, wrongdoing, injury, or damages, or of any wrongful conduct, acts, or omissions on the part of any of the Releasees, or of any infirmity of any defense, or of any damages to Lead Plaintiff or any other Settlement Class Member.

3. Why is this a class action?

In a class action, one or more persons and/or entities, called plaintiffs, sue on behalf of all persons and/or entities who have similar claims. All of these persons and/or entities are referred to collectively as a class, and these individual persons and/or entities are known as class members. One court resolves all of the issues for all class members, except for those class members who exclude themselves from the class.

4. Why is there a Settlement?

The Parties participated in a mediation session with Robert A. Meyer of JAMS on April 26, 2024. The mediation was unsuccessful. However, in April 2026, the Parties recommenced settlement discussions with the assistance of Mr. Meyer. During April through July 2026, Mr. Meyer continued to broker a potential settlement. On July 30, 2026, following weeks of negotiations, Mr. Meyer issued a mediator's proposal. On August 3, 2026, the Parties accepted the mediator's proposal and reached an agreement in principle to resolve all claims in the Action for a cash payment of $25.0 million.

Defendants have denied, and continue to deny, that they engaged in any wrongdoing of any kind, including, without limitation, that they committed any act or omission giving rise to any liability or violation of the law. Specifically, Defendants have denied, and continue to deny, each and all of the claims and contentions alleged in this Action, along with all charges of wrongdoing or liability against them arising out of any of the conduct, statements, acts, or omissions alleged, or that could have been alleged, in this Action. Defendants have denied, and continue to deny, that they violated or breached any law, regulation, or duty owed to Plaintiffs or the Settlement Class, failed to disclose any material information to investors, acted in any deceitful manner, or that their public statements were false or misleading, or that Plaintiffs and the Settlement Class suffered any damages or were harmed by the conduct alleged in the Action. Defendants have asserted, and continue to assert, that their conduct was at all times proper and in compliance with all applicable provisions of law, and that the claims asserted against Defendants are without merit. In addition, Defendants maintain that they have meritorious defenses to all of the claims alleged in the Action.

Although Plaintiffs believe that the claims asserted in the Action have merit, Plaintiffs and Lead Counsel are mindful of inherent problems of proof, possible defenses to the violations asserted in the litigation, and possible limitations on damages. These risks include: (1) the fact that Biogen's stock price rose on November 4, 2020, when the corrective disclosure was issued, and only fell the next day; (2) the fact that Plaintiffs' theory of liability depends on the precise timing of incorporation of the corrective information into Biogen's stock price; (3) the risk that Plaintiffs could not show that the November 9 stock drop was attributable to Defendants' fraud given the intervening advisory committee meeting and vote; (4) the risk of proving liability that arises from the fact that the FDA ultimately approved aducanumab; (5) the risk of showing that the remaining statement had price impact; and (6) the difficulty of proving that Defendants' statements were false and made with scienter.

This matter has not gone to trial, and the Court has not decided the Action in favor of either Plaintiffs or Defendants. Instead, Plaintiffs and Defendants have agreed to settle the case. Plaintiffs and Lead Counsel believe the Settlement is best for all Settlement Class Members because of the risks associated with continued litigation and the nature of the defenses raised by Defendants. Even if Plaintiffs were to win at trial, and also prevail on any appeal, Plaintiffs might not be able to collect some or any of the judgment they could be awarded.

5. How do I know if I am part of the Settlement?

The Settlement Class consists of all persons and entities who purchased or otherwise acquired the common stock of Biogen between October 22, 2019, and November 5, 2020, inclusive, subject to the exclusions in Question 6 below.

6. Are there exceptions to being included?

Yes. Excluded from the Settlement Class are Defendants, members of the immediate family of Defendants Vounatsos, Sandrock, and former defendant Samantha Budd-Haeberlein, the officers and directors of Biogen during the Class Period and any members of their immediate families, and

Defendants' legal representatives, heirs, agents, affiliates, successors or assigns, and any entity in which Defendants or their immediate families have or had a controlling interest. Also excluded from the Settlement Class are those Persons who submit a valid and timely request for exclusion as described below in the response to Question 11.

7. I am still not sure whether I am included.

If you are still not sure whether you are included in the Settlement Class, you can ask for free help. For more information, you can contact the Claims Administrator, Strategic Claims Services, by phone at (866) 274-4004, by email at info@strategicclaims.net, or by facsimile at (610) 565-7985; visit the website www.strategicclaims.net/Biogen2019; or fill out and return the Claim Form described in Question 9, to see if you qualify.

8. What does the Settlement provide?

a. What is the Settlement Fund?

The proposed Settlement provides for Biogen to pay or cause its insurers to pay twenty-five million dollars ($25,000,000) into an escrow account. The Settlement Amount plus any interest earned thereon is referred to as the "Settlement Fund." The Settlement is subject to Court approval. Also, subject to the Court's approval, a portion of the Settlement Fund will be used to pay attorneys' fees with interest to Lead Counsel, and reasonable Litigation Expenses to Lead Counsel and Plaintiffs. A portion of the Settlement Fund also will be used to pay taxes due on interest earned by the Settlement Fund, if necessary, and the costs of the claims administration, including the costs of printing and mailing and/or emailing notices and the costs of publishing notices. After the foregoing deductions from the Settlement Fund have been made, the amount remaining (the "Net Settlement Fund") will be distributed to Settlement Class Members who submit timely, valid claims, according to the Plan of Allocation to be approved by the Court.

b. What can you expect to receive under the proposed Settlement?

Your share of the Net Settlement Fund will depend on: (i) the number of claims filed; (ii) the dates you purchased and sold Biogen common stock; (iii) the prices of your purchases and sales; (iv) the amount of administrative costs, including the costs of notice; and (v) the amount awarded by the Court to Lead Counsel for attorneys' fees and to Lead Counsel and Plaintiffs for Litigation Expenses.

The Net Settlement Fund will be distributed to Settlement Class Members who submit a Claim Form and whose claims for recovery are allowed by the Claims Administrator pursuant to the terms of the Stipulation or by order of the Court in accordance with the proposed Plan of Allocation below ("Authorized Claimants"). The proposed Plan of Allocation reflects Plaintiffs' contention that because of the alleged misrepresentations made by Defendants, the price of Biogen common stock was artificially inflated during the Class Period, and that certain subsequent disclosures caused reductions in the inflated price of Biogen common stock. The proposed Plan of Allocation also reflects that the Dismissed Claims were significantly weaker based on both substantive and procedural grounds. Defendants have denied and continue to deny these allegations and any and all allegations of wrongdoing, fault, liability, or damage whatsoever asserted in the Action.

PROPOSED PLAN OF ALLOCATION OF THE NET SETTLEMENT FUND

The Plan of Allocation is a matter separate and apart from the proposed Settlement, and any decision by the Court concerning the Plan of Allocation shall not affect the validity or finality of the proposed Settlement. The Court may approve the Plan of Allocation with or without modifications, or another plan of allocation, without further notice to Settlement Class Members. Any orders regarding a

modification of the Plan of Allocation will be posted to the Claims Administrator's website, www.strategicclaims.net/Biogen2019.

The objective of the Plan of Allocation is to equitably distribute the Net Settlement Fund among Settlement Class Members who submit timely and valid Claim Forms and whose claims are allowed by the Claims Administrator or by order of the Court. The Plan of Allocation reflects Plaintiffs' contention that Defendants' alleged misstatements artificially inflated the price of Biogen common stock during the Class Period, and that certain subsequent disclosures reduced that artificial inflation. Defendants deny all allegations of wrongdoing, fault, liability, and damages.

The Plan of Allocation also reflects that claims based on purchases of Biogen common stock from October 22, 2019 through July 21, 2020 faced materially greater litigation risks than claims based on purchases from July 22, 2020 through November 5, 2020. Accordingly, the Net Settlement Fund will be divided into two pools: 80% of the Settlement Amount, or $20 million, for claims based on purchases of Biogen common stock from July 22, 2020 through November 5, 2020 (the "Active Claims"), and 20% of the Settlement Amount, or $5 million, for claims based on purchases from October 22, 2019 through July 21, 2020 (the "Dismissed Claims").

The Claims Administrator will calculate a Recognized Loss for each Claimant under the formula set forth below. The Recognized Loss formula is not intended to estimate the amount that a Settlement Class Member might have recovered after trial, nor is it an estimate of the amount that will be paid to Authorized Claimants under the Settlement. The Recognized Loss formula is only the basis for allocating the Net Settlement Fund among Authorized Claimants. Payment in this manner shall be deemed conclusive against all Authorized Claimants. No distribution will be made on a claim where the potential distribution amount is less than ten dollars ($10.00) in cash.

Each Authorized Claimant with Active Claims will receive the same proportion of the Active Claims pool that the claimant's Recognized Loss for Active Claims bears to the total Recognized Losses of all Authorized Claimants with Active Claims. Each Authorized Claimant with Dismissed Claims will receive the same proportion of the Dismissed Claims pool that the claimant's Recognized Loss for Dismissed Claims bears to the total Recognized Losses of all Authorized Claimants with Dismissed Claims. If a claimant has both Active Claims and Dismissed Claims, the Claims Administrator will calculate and pay that claimant's recovery separately from each applicable pool.

If any funds remain in the Net Settlement Fund by reason of uncashed checks, or otherwise, after the Claims Administrator has made reasonable and diligent efforts to have Authorized Claimants who are entitled to participate in the distribution of the Net Settlement Fund cash their distribution checks, then any balance remaining in the Net Settlement Fund six (6) months after the initial distribution of such funds shall be used: (i) first, to pay any amounts mistakenly omitted from the initial distribution to Authorized Claimants who would receive at least a $10.00 payment; (ii) second, to pay any additional Notice and Administration Costs incurred in administering the Settlement; and (iii) finally, to make a second distribution to Authorized Claimants who cashed their checks from the initial distribution and who would receive at least $10.00 from such second distribution, after payment of the estimated costs or fees to be incurred in administering the Net Settlement Fund and in making this second distribution, if such second distribution is economically feasible. If, after the Claims Administrator has made reasonable and diligent efforts to have Authorized Claimants who are entitled to participate in this Settlement cash their checks, any funds remain in the Net Settlement Fund six (6) months after the second distribution, if undertaken, or six (6) months after the determination not to undertake a second distribution, those funds shall be donated to the Massachusetts Legal Assistance Corporation.

THE BASIS FOR CALCULATING YOUR RECOGNIZED LOSS:

Each Authorized Claimant shall be allocated a *pro rata* share of the of the Active Claims fund, the Dismissed Claims fund, or both, as applicable, based on his, her, or its Recognized Loss in each fund as compared to the total Recognized Losses in that fund of all Authorized Claimants participating in that fund. Recognized Losses will be calculated as follows:

For Biogen common stock purchased during the Class Period, the Recognized Loss shall be calculated as follows:

A. For shares retained at the end of trading on February 2, 2021, the Recognized Loss shall be the lesser of:

   (i) $25.21 per share; or

   (ii) the difference between the purchase price per share and $255.32 per share[1].

B. For shares sold on or before November 5, 2020, the Recognized Loss per share shall be $0.00.

C. For shares sold after November 5, 2020, and on or before February 2, 2021, the Recognized Loss shall be the lesser of:

   (i) $25.21 per share; or

   (ii) the difference between the purchase price per share and the average closing price per share as of the date of sale provided in Table A below.

Table A

Date	Closing Price	Average Closing Price	Date	Closing Price	Average Closing Price
11/5/2020	$328.90	$328.90	12/18/2020	$249.62	$249.88
11/6/2020	$328.90	$328.90	12/21/2020	$248.32	$249.84
11/9/2020	$236.26	$298.02	12/22/2020	$247.87	$249.78
11/10/2020	$236.34	$282.60	12/23/2020	$251.20	$249.82
11/11/2020	$244.03	$274.89	12/24/2020	$248.89	$249.79
11/12/2020	$241.55	$269.33	12/28/2020	$244.15	$249.63
11/13/2020	$248.59	$266.37	12/29/2020	$243.46	$249.47
11/16/2020	$250.96	$264.44	12/30/2020	$243.58	$249.31
11/17/2020	$248.81	$262.70	12/31/2020	$244.86	$249.20
11/18/2020	$240.98	$260.53	1/4/2021	$242.95	$249.04
11/19/2020	$244.01	$259.03	1/5/2021	$246.39	$248.98
11/20/2020	$244.15	$257.79	1/6/2021	$247.75	$248.95

[1] Pursuant to Section 21D(e)(1) of the Private Securities Litigation Reform Act of 1995, "in any private action arising under this title in which the plaintiff seeks to establish damages by reference to the market price of a security, the award of damages to the plaintiff shall not exceed the difference between the purchase or sale price paid or received, as appropriate, by the plaintiff for the subject security and the mean trading price of that security during the 90-day period beginning on the date on which the information correcting the misstatement or omission that is the basis for the action is disseminated." $255.32 per share was the mean (average) daily closing trading price of the Company's shares during the 90-day period beginning on November 5, 2020, through and including February 2, 2021.

Table A					
Date	Closing Price	Average Closing Price	Date	Closing Price	Average Closing Price
11/23/2020	$243.38	$256.68	1/7/2021	$250.44	$248.98
11/24/2020	$242.51	$255.67	1/8/2021	$252.54	$249.06
11/25/2020	$241.75	$254.74	1/11/2021	$267.52	$249.47
11/27/2020	$243.78	$254.06	1/12/2021	$267.39	$249.86
11/30/2020	$240.17	$253.24	1/13/2021	$266.67	$250.22
12/1/2020	$243.16	$252.68	1/14/2021	$280.29	$250.85
12/2/2020	$246.92	$252.38	1/15/2021	$275.84	$251.36
12/3/2020	$244.09	$251.96	1/19/2021	$273.84	$251.81
12/4/2020	$245.87	$251.67	1/20/2021	$270.28	$252.17
12/7/2020	$243.68	$251.31	1/21/2021	$270.12	$252.51
12/8/2020	$246.43	$251.10	1/22/2021	$269.44	$252.83
12/9/2020	$244.75	$250.83	1/25/2021	$275.54	$253.25
12/10/2020	$242.98	$250.52	1/26/2021	$271.67	$253.59
12/11/2020	$241.43	$250.17	1/27/2021	$265.15	$253.80
12/14/2020	$245.25	$249.99	1/28/2021	$267.87	$254.04
12/15/2020	$248.73	$249.94	1/29/2021	$282.61	$254.54
12/16/2020	$248.19	$249.88	2/1/2021	$278.46	$254.94
12/17/2020	$250.24	$249.89	2/2/2021	$277.72	$255.32

To the extent a Claimant had a trading gain or "broke even" from his, her, or its overall transactions in Biogen common stock during the Class Period, the value of the Recognized Loss will be zero and the Claimant will not be entitled to a share of the Net Settlement Fund. To the extent that a Claimant suffered a trading loss on his, her, or its overall transactions in Biogen's common stock during the Class Period, but that trading loss was less than the Recognized Loss calculated above, then the Recognized Loss shall be limited to the amount of the Claimant's actual trading loss.

For purposes of calculating your Recognized Loss, the date of purchase, acquisition or sale is the "contract" or "trade" date and not the "settlement" or "payment" date. The receipt or grant by gift, inheritance, or operation of law of Biogen's common stock shall not be deemed a purchase or acquisition of Biogen's common stock for the calculation of a Claimant's Recognized Loss. The covering purchase of a short sale is not an eligible purchase. Only purchases of publicly traded shares of Biogen common stock are eligible purchases (CUSIP number: 09062X103).

For purposes of calculating your Recognized Loss, all purchases, acquisitions, and sales shall be matched on a first-in, first-out ("FIFO") basis in chronological order. Therefore, on the Proof of Claim and Release Form enclosed with this Notice, you must provide all of your purchases, acquisitions, and sales of Biogen's common stock during the period from October 22, 2019 through and including February 2, 2021.

Payment pursuant to the Plan of Allocation approved by the Court shall be conclusive against all Authorized Claimants. No person shall have any claim against Plaintiffs, Lead Counsel, Defendants, Defendants' Counsel, the Releasees, the Claims Administrator, the Escrow Agent, or any other agent designated by Lead Counsel based on distribution determinations or claim rejections made substantially in accordance with the Stipulation, the Plan of Allocation, or further orders of the Court. Each Claimant

shall be deemed to have submitted to the jurisdiction of the Court with respect to the Claimant's Claim Form. All persons involved in the review, verification, calculation, tabulation, or any other aspect of the processing of the claims submitted in connection with the Settlement, or otherwise involved in the administration or taxation of the Settlement Fund or the Net Settlement Fund, shall be released and discharged from any and all claims arising out of such involvement, and all Settlement Class Members, whether or not they are to receive payment from the Net Settlement Fund, will be barred from making any further claim against the Net Settlement Fund beyond the amount allocated to them as provided in any distribution orders entered by the Court.

9. How can I get a payment?

To qualify for a payment, you must send in a form entitled "Proof of Claim and Release Form." This Claim Form is attached to this Notice. You may also obtain a Claim Form atwww.strategicclaims.net/Biogen2019. Read the instructions carefully, fill out the form, and sign it in the location indicated. The Claim Form may be submitted in one of two ways: (1) completing and submitting it electronically at www.strategicclaims.net/Biogen2019 **by 11:59 p.m. ET on January 19, 2027**; or (2) mailing the Claim Form together with all documentation requested in the form, **postmarked no later than January 19, 2027**, to:

Biogen Inc. Securities Litigation
c/o Strategic Claims Services
P.O. Box 230
600 N. Jackson St., Ste. 205
Media, PA 19063
Fax: (610) 565-7985
info@strategicclaims.net

The Claims Administrator will process your claim and determine whether you are an Authorized Claimant.

If your claim is rejected in whole or in part and you wish to contest that determination, you must, within ten (10) calendar days after the date the Claims Administrator mails the rejection or partial rejection notice, submit to the Claims Administrator a notice and statement of reasons for contesting the determination, together with any supporting documentation, and request Court review. If the issue cannot otherwise be resolved, Lead Counsel will present the request for review to the Court.

10. What am I giving up by receiving a payment and staying in the Settlement Class?

Unless you exclude yourself from the Settlement Class by the January 19, 2027 deadline, you will remain a member of the Settlement Class, receive your share of the Net Settlement Fund if you are a Settlement Class Member and submitted a valid Claim Form, and will be bound by the release of claims against the Defendants and Defendants' Releasees upon the Effective Date. That means you and all other Settlement Class Members and each of their respective parent entities, associates, affiliates, subsidiaries, predecessors, successors, assigns, attorneys, Immediate Family Members, heirs, representatives, administrators, executors, devisees, legatees, and estates will release (agreeing never to sue, continue to sue, or be part of any other lawsuit) each and every one of Released Plaintiffs' Claims against Defendants and Defendants' Releasees, and shall be forever barred and enjoined from commencing, instituting, assisting, prosecuting, or continuing to prosecute any action or other proceeding in any court of law or equity, arbitration tribunal, administrative forum, or any other forum, asserting any of Released Plaintiffs' Claims (including, without limitation, Unknown Claims) against Defendants and Defendants' Releasees.

"Claims" means any and all manner of claims, demands, rights, actions, potential actions, causes of action, liabilities, duties, damages, losses, diminutions in value, obligations, agreements, suits, fees, attorneys' fees, expert or consulting fees, debts, expenses, costs, sanctions, judgments, decrees, matters, issues and/or controversies of any kind or nature whatsoever, whether known or Unknown Claims, contingent or absolute, liquidated or not liquidated, accrued or unaccrued, suspected or unsuspected, disclosed or undisclosed, apparent or not apparent, foreseen or unforeseen, matured or not matured, which now exist, or heretofore or previously existed, or may hereafter exist (including, but not limited to, any claims arising under federal, state, local, or foreign law, common law, bankruptcy law, statute, rule, or regulation, whether individual, class, direct, derivative, representative, on behalf of others, legal, equitable, regulatory, governmental, or of any other type or in any other capacity.

"Released Plaintiffs' Claims" means any and all Claims, including Unknown Claims, that have been, could have been, or in the future can or might be asserted in any federal, state, local, or foreign court, tribunal, forum or proceeding by or on behalf of any of the Plaintiffs' Releasees against any one or more of the Defendants' Releasees, regardless of whether any such Defendants' Releasee was named, served with process, or appeared in the Action, which directly or indirectly arise out of, are based upon, or relate in any way, directly or indirectly, to: (i) any of the allegations, acts, transactions, facts, events, matters, occurrences, representations, or omissions involved, set forth, alleged, or referred to, in the Action, or which could have been alleged in the Action; and (ii) the purchase, acquisition, holding, sale, or disposition of any Biogen securities during the Class Period. Released Plaintiffs' Claims do not include any claims to enforce the terms of the Settlement, and any claims of any person or entity who or which submits a request for exclusion that is accepted by the Court; provided, however, that Released Plaintiffs' Claims shall include all Claims of Nadia Shash, Amjad Khan, Albert Aftoora, PolyCon Solutions LLC, and Raymond Pawloski, none of whom shall have the right to request exclusion from the Settlement Class.

"Unknown Claims" means any Released Claims which Plaintiffs, any other Settlement Class Member, or each of the Defendants or any of the other Releasees, does not know or suspect to exist in his, her, their, or its favor at the time of the release which, if known by him, her, them, or it, might have affected his, her, their, or its settlement with and release of any of the other Releasees, or might have affected his, her, their, or its decision not to opt-out or object to this Settlement. With respect to any and all Released Claims, the Parties stipulate and agree that, upon the Effective Date of the Settlement, the Parties shall expressly waive, and each of the other Settlement Class Members and Releasees shall be deemed to have waived, and by operation of the final Judgment shall have waived, the provisions, rights and benefits of California Civil Code § 1542, and any law of any state or territory of the United States, which is similar, comparable or equivalent to California Civil Code § 1542, which provides:

> A general release does not extend to claims that the creditor or releasing party does not know or suspect to exist in his or her favor at the time of executing the release and that, if known by him or her, would have materially affected his or her settlement with the debtor or released party.

"Defendants' Releasees" means: (a) Biogen, its past, present, and future, direct or indirect, parent entities, associates, affiliates, and subsidiaries, each and all of their respective past, present, and future directors, officers and executives (including but not limited to Vounatsos, Sandrock, and Samantha Budd-Haeberlein), partners, stockholders, predecessors, successors, and employees, and in their capacity as such, each and all of their underwriters, advisors, attorneys, auditors, accountants, investment bankers, contractors, consultants, trustees, insurers, co-insurers, reinsurers, representatives, and assigns; (b) Defendants Vounatsos and Sandrock, and Samantha Budd-

Haeberlein, as well as their respective past, present, and future spouses, parents, siblings, children, grandparents, and grandchildren, the past, present, and future spouses of their respective parents, siblings and children, and the past, present, and future parents and siblings of their respective spouses, including step and adoptive relationships; (c) any and all persons, firms, trusts, corporations, and other entities in which any of the Defendants or any past, present, and future directors or officers of Biogen has a financial interest or was a sponsor, founder, settlor, or creator of the entity, and, in their capacity as such, any and all officers, directors, employees, trustees, beneficiaries, settlors, creators, attorneys, consultants, agents, or representatives of any such person, firm, trust, corporation or other entity; and (d) in their capacity as such, the legal representatives, heirs, executors, administrators, predecessors, successors, predecessors-in-interest, successors-in-interest, and assigns of any of the foregoing.

11. How do I get out of the Settlement?

If you do not want to receive a payment from this Settlement, and you want to keep any right you may have to sue or continue to sue Defendants or Defendants' Releasees on your own, at your own expense, about the claims being released in this Settlement, then you must take steps to exclude yourself from the Settlement. To exclude yourself from the Settlement, you must mail or otherwise deliver a written request that (A) clearly indicates your name, address, phone number, and email contact information (if any) and states that you "request to be excluded from the Settlement Class in *Shash v. Biogen Inc., et al.*, Case No. 1:21-cv-10479-IT (D. Mass.)" and (B) states the date, number of shares, and dollar amount of each purchase and/or acquisition of Biogen common stock during the Class Period, any sale transactions during the Class Period, and the number of shares of Biogen common stock held by you as of the close of trading on October 21, 2019 and November 5, 2020. Such request for exclusion must be submitted with documentary proof: (i) of each purchase and, if applicable, sale transaction of Biogen common stock during the Class Period as well as the date, number of shares, and dollar amount of each purchase/acquisition and sale; and (ii) demonstrating your status as a beneficial owner of the Biogen common stock. Any such request for exclusion must be signed and submitted by you, as the beneficial owner, under penalty of perjury. You must mail your exclusion request, to be **received no later than January 19, 2027**, to the Claims Administrator at the following address:

Biogen Inc. Securities Litigation
c/o Strategic Claims Services
P.O. Box 230
600 N. Jackson St., Ste. 205
Media, PA 19063

You cannot exclude yourself by telephone or by email.

If you properly exclude yourself, you will *not* receive a payment from the Net Settlement Fund, you cannot object to the Settlement, and you will not be legally bound by the judgment in this case.

12. If I do not exclude myself, can I sue Defendants or Defendants' Releasees for the same thing later?

No. Unless you followed the procedure outlined in this Notice to exclude yourself, you give up any right to sue Defendants or Defendants' Releasees for the claims being released in this Settlement. If you have a pending lawsuit related to any Released Claims, speak to your lawyer in that case immediately, since you must exclude yourself from this Settlement Class to continue your own lawsuit.

13. Do I have a lawyer in this case?

The Court appointed The Rosen Law Firm, P.A. as Lead Counsel to represent you and the other Settlement Class Members. If you want to be represented by your own lawyer, you may hire one at your own expense. Contact information for The Rosen Law Firm, P.A. is provided below.

14. How will the lawyers be paid?

Lead Counsel has expended considerable time litigating this Action on a contingent fee basis and has paid for the expenses of the case themselves. Lead Counsel has not been paid attorneys' fees or reimbursed for their expenses in advance of this Settlement. Lead Counsel has done so with the expectation that, if they are successful in recovering money for the Settlement Class, they will receive attorneys' fees and be reimbursed for their litigation expenses from the Settlement Fund, as is customary in this type of litigation. Lead Counsel will not receive attorneys' fees or be reimbursed for their litigation expenses except from the Settlement Fund. Therefore, Lead Counsel will apply to the Court for an award of attorneys' fees in an amount not to exceed one-third of the Settlement Amount plus interest, and reimbursement of Litigation Expenses of no more than $1,900,000 plus interest. The Court may award less than these amounts. Any amounts awarded by the Court will come out of the Settlement Fund.

15. How do I tell the Court that I do not like the Settlement?

You can tell the Court you do not agree with the Settlement, any part of the Settlement, and/or with Lead Counsel's motion for attorneys' fees and Litigation Expenses, and/or that you think the Court should not approve the Settlement, by filing a written objection with the Court and serving copies on Lead Counsel and Defense Counsel stating that you object to the Settlement in the matter of *Shash v. Biogen Inc., et al.*, Case No. 1:21-cv-10479-IT (D. Mass.). Be sure to include: (1) your name, address, email contact information (if any), and telephone number; (2) a list of all purchases and sales of Biogen common stock during the Class Period (to demonstrate that you are a Settlement Class Member), including the number of shares of stock and the dates of each purchase and sale; (3) all grounds for the objection, including any legal support known to you or your counsel; (4) the name, address, email address, and telephone number of all counsel, if any, who represent you, including your former or current counsel; and (5) the number of times you and/or your counsel has filed an objection to a class action settlement in the last five years, the nature of each such objection in each case, the jurisdiction in each case, and the name of the issuer of the security or seller of the product or service at issue in each case. Attendance at the Settlement Fairness Hearing is not necessary. Objectors wishing to be heard orally at the Settlement Fairness Hearing are required to indicate in their written objection (or in a separate writing that is submitted and served on the Parties at least twenty-one (21) calendar days prior to the Settlement Fairness Hearing) that they intend to appear at the Settlement Fairness Hearing and identify any witnesses they may call to testify or exhibits they intend to introduce into evidence at the Settlement Fairness Hearing. Be sure to serve copies of any objections, papers, and briefs to **each** of the addresses listed below, to be **received no later than February 12, 2027**:

Clerk's Office	***Lead Counsel***	***Defendants' Counsel***
Clerk of the Court United States District Court District of Massachusetts 1 Courthouse Way, Suite 2300 Boston, MA 02210	Jonathan Horne The Rosen Law Firm, P.A. 275 Madison Ave 40th Floor New York, NY 10016	Audra J. Soloway Paul, Weiss, Rifkind, Wharton & Garrison LLP 1285 Ave. of the Americas New York, NY 10019

16. What is the difference between objecting and requesting exclusion?

Objecting is simply telling the Court you do not like something about the Settlement or some portion thereof. You can object only if you stay in the Settlement Class. Requesting exclusion is telling the Court you do not want to be part of the Settlement Class and Settlement. If you exclude yourself, you cannot object to the Settlement because it no longer concerns you. If you stay in the Settlement Class and object, but your objection is overruled, you will not be allowed a second opportunity to exclude yourself.

17. When and where will the Court decide whether to approve the Settlement?

The Court will hold a Settlement Fairness Hearing on **March 5, 2027, at 10:00 a.m. ET**, at the United States District Court for the District of Massachusetts, 1 Courthouse Way, Courtroom 9, Boston, MA 02210. The Court reserves the right to hold the Settlement Fairness Hearing telephonically or by other virtual means. In the event the Court decides to hold the Settlement Fairness Hearing telephonically or by other virtual means, Lead Counsel will direct the Claims Administrator to update its website, on the page dedicated to this Settlement, to include the telephone number or other virtual means to access the Settlement Fairness Hearing.

18. Do I have to come to the hearing?

No. Lead Counsel will answer any questions the Court may have. However, you are welcome to attend at your own expense. If you send an objection, you do not have to come to Court to talk about it. As long as you file and serve your written objection on time, the Court will consider it.

19. What happens if I do nothing at all?

If you do nothing, you will not receive a payment from the Settlement. However, unless you exclude yourself, you will not be able to start a lawsuit, continue with a lawsuit, or be part of any other lawsuit against Defendants or Defendants' Releasees about the Released Claims (as defined in the Stipulation) ever again.

SPECIAL NOTICE TO BROKERS AND OTHER NOMINEES

If, during the Class Period, you purchased Biogen common stock for the beneficial interest of a person or organization other than yourself, and held such stock until November 5, 2020, the Court has directed that, WITHIN 10 CALENDAR DAYS OF YOUR RECEIPT OF THE CLAIMS ADMINISTRATOR'S LETTER, you either: (a) provide to the Claims Administrator the name, last known address, and email address (to the extent known) of each person or organization for whom or which you purchased such Biogen common stock during such time period; (b) request a link to the webpage hosting the Long Notice and Claim Form and email the link to the webpage hosting the Long Notice and Claim Form directly to each beneficial owner for whom you are nominee or custodian within ten (10) calendar days after receipt thereof; or (c) request copies of the Postcard Notice sufficient to send to each beneficial owner for whom you are nominee or custodian and mail the Postcard Notices to each such beneficial owner within ten (10) calendar days after receipt thereof. If you choose to follow alternative procedures (b) or (c), the Court has directed that, upon such emailing or mailing, you send a statement to the Claims Administrator confirming that the emailing or mailing was made as directed. You are entitled to reimbursement from the Settlement Fund of your reasonable out-of-pocket expenses actually incurred in connection with the foregoing, up to a maximum of $0.02 per link to the webpage hosting the Long Notice and Claim Form emailed; $0.02 per Postcard Notice actually mailed, plus postage at the pre-sort rate used by the Claims Administrator; or up to a maximum of $0.02 per name, last known address, and email address provided to the Claims Administrator. Those expenses will be paid upon request and submission

of appropriate supporting documentation. All communications regarding the foregoing should be addressed to the Claims Administrator at the address listed on page 3 above.

DATED: OCTOBER 27, 2026

BY ORDER OF THE UNITED STATES
DISTRICT COURT FOR THE
DISTRICT OF MASSACHUSETTS

PROOF OF CLAIM AND RELEASE FORM

Deadline for Submission: JANUARY 19, 2027

IF YOU PURCHASED OR OTHERWISE ACQUIRED PUBLICLY-TRADED BIOGEN INC. ("BIOGEN") COMMON STOCK BETWEEN OCTOBER 22, 2019 AND NOVEMBER 5, 2020, BOTH DATES INCLUSIVE (THE "CLASS PERIOD") YOU ARE A "SETTLEMENT CLASS MEMBER" AND YOU MAY BE ENTITLED TO SHARE IN THE NET SETTLEMENT FUND. (EXCLUDED FROM THE SETTLEMENT CLASS ARE DEFENDANTS, MEMBERS OF THE IMMEDIATE FAMILY OF DEFENDANTS VOUNATSOS, SANDROCK, AND FORMER DEFENDANT SAMANTHA BUDD-HAEBERLEIN, THE OFFICERS AND DIRECTORS OF BIOGEN DURING THE CLASS PERIOD AND ANY MEMBERS OF THEIR IMMEDIATE FAMILIES, AND DEFENDANTS' LEGAL REPRESENTATIVES, HEIRS, AGENTS, AFFILIATES, SUCCESSORS OR ASSIGNS, AND ANY ENTITY IN WHICH DEFENDANTS OR THEIR IMMEDIATE FAMILIES HAVE OR HAD A CONTROLLING INTEREST. ALSO EXCLUDED FROM THE SETTLEMENT CLASS ARE THOSE PERSONS WHO SUBMIT A VALID AND TIMELY REQUEST FOR EXCLUSION IN ACCORDANCE WITH THE PRELIMINARY APPROVAL ORDER.)

IF YOU ARE A SETTLEMENT CLASS MEMBER, YOU MUST COMPLETE AND SUBMIT THIS PROOF OF CLAIM AND RELEASE FORM ("CLAIM FORM") TO BE ELIGIBLE TO SHARE IN THE SETTLEMENT BENEFITS. **YOU CAN COMPLETE AND SUBMIT THE ELECTRONIC VERSION OF THIS CLAIM FORM BY 11:59 P.M. ET ON JANUARY 19, 2027 AT WWW.STRATEGICCLAIMS.NET/BIOGEN2019/.**

IF YOU DO NOT COMPLETE AND SUBMIT AN ELECTRONIC VERSION OF THIS CLAIM FORM, YOU MUST COMPLETE AND SIGN THIS CLAIM FORM AND MAIL IT BY FIRST-CLASS MAIL, POSTMARKED NO LATER THAN JANUARY 19, 2027, TO STRATEGIC CLAIMS SERVICES, THE CLAIMS ADMINISTRATOR, AT THE FOLLOWING ADDRESS:

Biogen Inc. Securities Litigation
c/o Strategic Claims Services
600 N. Jackson St., Ste. 205
P.O. Box 230
Media, PA 19063
Fax: (610) 565-7985
info@strategicclaims.net

SUBMIT YOUR CLAIM ONLY TO THE CLAIMS ADMINISTRATOR. DO NOT MAIL OR DELIVER YOUR CLAIM TO THE COURT OR TO ANY OF THE PARTIES OR THEIR COUNSEL, AS ANY SUCH CLAIM WILL BE DEEMED NOT TO HAVE BEEN SUBMITTED.

YOUR FAILURE TO SUBMIT YOUR CLAIM BY JANUARY 19, 2027, MAY SUBJECT YOUR CLAIM TO REJECTION AND MAY PRECLUDE YOU FROM RECEIVING ANY MONEY IN CONNECTION WITH THE SETTLEMENT OF THIS ACTION. IF YOU ARE A SETTLEMENT CLASS MEMBER AND DO NOT SUBMIT A PROPER CLAIM FORM, YOU WILL NOT SHARE IN THE SETTLEMENT BUT YOU NEVERTHELESS WILL BE BOUND BY THE COURT'S JUDGMENT UNLESS YOU EXCLUDE YOURSELF. SUBMISSION OF A CLAIM FORM DOES NOT GUARANTEE THAT YOU WILL SHARE IN THE PROCEEDS OF THE SETTLEMENT.

CLAIMANT'S STATEMENT

1. I (we) purchased or otherwise acquired publicly-traded Biogen Inc. ("Biogen") common stock during the Class Period. (Do not submit this Proof of Claim and Release Form ("Claim Form") if you did not purchase or otherwise acquire publicly-traded Biogen common stock during the Class Period.)

2. By submitting this Claim Form, I (we) state that I (we) believe in good faith that I am (we are) a Settlement Class Member(s) as defined above and in the Notice of Pendency and Proposed Settlement of Class Action (the "Long Notice"), or am (are) acting for such person(s); that I am (we are) not a Defendant(s) in the Action or anyone excluded from the Settlement Class; that I (we) have read and understand the Long Notice; that I (we) believe that I am (we are) entitled to receive a share of the Net Settlement Fund, as defined in the Long Notice; that I (we) elect to participate in the proposed Settlement described in the Long Notice; and that I (we) have not filed a request for exclusion. (If you are acting in a representative capacity on behalf of a Settlement Class Member [e.g., as an executor, administrator, trustee, or other representative], you must submit evidence of your current authority to act on behalf of that Settlement Class Member. Such evidence would include, for example, letters testamentary, letters of administration, or a copy of the trust documents.)

3. I (we) consent to the jurisdiction of the Court with respect to all questions concerning the validity of this Claim Form. I (we) understand and agree that my (our) claim may be subject to investigation and discovery under the Federal Rules of Civil Procedure, provided that such investigation and discovery shall be limited to my (our) status as a Settlement Class Member(s) and the validity and amount of my (our) claim. No discovery shall be allowed on the merits of the Action or Settlement in connection with processing of the Claim Form.

4. I (we) have set forth where requested below all relevant information with respect to each purchase and/or acquisition of Biogen common stock, and each sale, if any, of such common stock. If the Claimant is an entity, I (we) have also identified on an attached sheet all beneficial owners of the entity and their percentage interests. I (we) agree to furnish additional information to the Claims Administrator to support this claim if requested to do so.

5. I (we) have enclosed photocopies of the stockbroker's confirmation slips, stockbroker's statements, or other documents evidencing each purchase and sale of publicly-traded Biogen common stock listed below in support of my (our) claim. (If any such documents are not in your possession, please obtain a copy or equivalent documents from your broker or tax advisor because these documents are necessary to prove and process your claim. **YOUR FAILURE TO SUBMIT COPIES OF OFFICIAL DOCUMENTS EVIDENCING YOUR PURCHASES AND/OR SALES MAY CAUSE THE CLAIMS ADMINISTRATOR TO REJECT YOUR CLAIM**.)

6. I (we) understand that the information contained in this Claim Form is subject to such verification as the Claims Administrator may request or as the Court may direct, and I (we) agree to cooperate in any such verification. (The information requested herein is designed to provide the minimum amount of information necessary to process most simple claims. The Claims Administrator may request additional information as required to calculate your Recognized Loss efficiently and reliably. In some cases, the Claims Administrator may condition acceptance of the claim based upon the production of additional information, including, where it could affect your Recognized Loss, information concerning transactions in any derivative securities such as options.)

7. Upon the Effective Date of the Settlement, as defined in the Stipulation, I (we) acknowledge that I (we), and any person or entity claiming through or on behalf of me (us), shall be deemed to have, and by operation of the Judgment shall have, fully, finally, and forever released, relinquished, and discharged each and every one of the "Released Plaintiffs' Claims" against Defendants and the "Defendants' Releasees," as those terms are defined in the Stipulation of Settlement, dated October 6, 2026 ("Stipulation").

8. Upon the Effective Date of the Settlement, as defined in the Stipulation, I (we) acknowledge that I (we), and any person or entity claiming through or on behalf of me (us), shall be forever barred and enjoined from commencing, instituting, assisting, prosecuting, or continuing to prosecute any action or other proceeding asserting any "Released Plaintiffs' Claims" against Defendants or the "Defendants' Releasees."

9. I (We) acknowledge that "Defendants' Releasees" and "Plaintiffs' Releasees" have the meanings laid out in the Stipulation.

10. I (We) acknowledge that "Released Claims" has the meaning laid out in the Stipulation.

11. I (We) acknowledge that "Unknown Claims" has the meaning laid out in the Stipulation.

12. I (We) acknowledge that the inclusion of "Unknown Claims" in the definition of claims released pursuant to the Stipulation was separately bargained for and is a material element of the Settlement of which this release is a part.

13. NOTICE REGARDING INSTITUTIONAL FILERS: Representatives with authority to file on behalf of (a) accounts of multiple Settlement Class Members and/or (b) institutional accounts with large numbers of transactions ("Representative Filers") must submit information regarding their transactions in an electronic spreadsheet format. If you are a Representative Filer, you must contact the Claims Administrator at efile@strategicclaims.net or visit their website at www.strategicclaims.net/Biogen2019/ to obtain the required file layout. Claims which are not submitted in electronic spreadsheet format and in accordance with the Claims Administrator's instructions may be subject to rejection. All Representative Filers MUST also submit a manually signed Claim Form for each Settlement Class Member, as well as proof of authority to file (see Item 2 of the Claimant's Statement), along with the electronic spreadsheet format. No claims submitted in electronic spreadsheet format will be considered to have been properly submitted unless the Claims Administrator issues to the Claimant a written acknowledgment of receipt and acceptance of electronically submitted data.

14. NOTICE REGARDING ONLINE FILING: Claimants who are not Representative Filers may submit their claims online using the electronic version of the Claim Form hosted at www.strategicclaims.net/Biogen2019/. If you are not acting as a Representative Filer, you do not need to contact the Claims Administrator prior to filing; you will receive an automated e-mail confirming receipt once your Claim Form has been submitted. If you are unsure if you should submit your claim as a Representative Filer, please contact the Claims Administrator by email at info@strategicclaims.net or by telephone toll-free at (866) 274-4004. If you are not a Representative Filer, but your claim contains a large number of transactions, the Claims Administrator may request that you also submit an electronic spreadsheet showing your transactions to accompany your Claim Form.

I. CLAIMANT INFORMATION

Beneficial Owner Name		
Address		
City	State	Zip Code
Foreign Province	Foreign Country	
Day Phone	Evening Phone	
Email		
Social Security Number (for individuals)	OR	Taxpayer Identification Number (for estates, trusts, corporations, etc.)

II. SCHEDULE OF TRANSACTIONS IN BIOGEN INC. ("BIOGEN") COMMON STOCK

Beginning Holdings:

A. State the total number of shares of publicly-traded Biogen common stock held at the close of trading on October 21, 2019 (*must be documented).* If none, write "zero" or "0."

Purchases:

B. Separately list each and every purchase and/or acquisition of publicly-traded Biogen common stock between October 22, 2019 and November 5, 2020, both dates inclusive, and provide the following information (*must be documented):*

Trade Date[2] (List Chronologically) (Month/Day/Year)	Number of Shares Purchased	Price per Share	Total Cost (Excluding Commissions, Taxes, and Fees)

Purchases During the 90-Day Lookback:

C. State the total number of shares of publicly-traded Biogen common stock purchased during the period from November 6, 2020 through and including February 2, 2021. If none, write "zero" or "0."

[2] "Trade Date" refers to the date the trade was initiated, not the settlement date.

Sales:

D. Separately list each and every sale of publicly-traded Biogen common stock between October 22, 2019 and February 2, 2021, both dates inclusive, and provide the following information (*must be documented*):

Trade Date (List Chronologically) (Month/Day/Year)	Number of Shares Sold	Price per Share	Amount Received (Excluding Commissions, Taxes, and Fees)

Ending Holdings:

E. State the total number of shares of publicly-traded Biogen common stock held at the close of trading on February 2, 2021 (*must be documented).* If none, write "zero" or "0."

If additional space is needed, attach separate, numbered sheets, giving all required information, substantially in the same format, and print your name and Social Security or Taxpayer Identification Number at the top of each sheet.

III. SUBSTITUTE FORM W-9

Request for Taxpayer Identification Number:

Enter the taxpayer identification number below for the Beneficial Owner(s). For most individuals, this is your Social Security Number. The Internal Revenue Service ("I.R.S.") requires such taxpayer identification number. If you fail to provide this information, your claim may be rejected.

Social Security Number (for individuals)	or	Taxpayer Identification Number (for estates, trusts, corporations, etc.)
_____		_____

IV. CERTIFICATION

I (We) submit this Proof of Claim and Release Form under the terms of the Stipulation described in the Long Notice. I (We) also submit to the jurisdiction of the United States District Court for the District of Massachusetts with respect to my (our) claim as a Settlement Class Member(s) and for purposes of enforcing the release and covenant not to sue set forth herein. I (We) further acknowledge that I am (we are) bound by and subject to the terms of any judgment that may be entered in the Action. I (We) have not submitted any other claim covering the same purchases or sales of publicly-traded Biogen common stock during the Class Period and know of no other Person having done so on my (our) behalf.

I (We) certify that I am (we are) NOT subject to backup withholding under the provisions of Section 3406 (a)(1)(c) of the Internal Revenue Code because: (a) I am (We are) exempt from backup withholding; or (b) I (We) have not been notified by the I.R.S. that I am (we are) subject to backup withholding as a result of a

failure to report all interest or dividends; or (c) the I.R.S. has notified me (us) that I am (we are) no longer subject to backup withholding.

NOTE: If you have been notified by the I.R.S. that you are subject to backup withholding, please strike out the language that you are not subject to backup withholding in the certification above.

UNDER THE PENALTIES OF PERJURY UNDER THE LAWS OF THE UNITED STATES, I (WE) CERTIFY THAT ALL OF THE INFORMATION I (WE) PROVIDED ON THIS PROOF OF CLAIM AND RELEASE FORM IS TRUE, CORRECT AND COMPLETE.

Signature of Claimant (If this claim is being made on behalf of Joint Claimants, then each must sign):

_____
(Signature)

_____
(Signature)

_____
(Capacity of person(s) signing, e.g. beneficial purchaser(s), executor, administrator, trustee, etc.)
☐ Check here if proof of authority to file is enclosed.
(See Item 2 under Claimant's Statement)

Date: _____

THIS CLAIM FORM MUST BE SUBMITTED ONLINE AT WWW.STRATEGICCLAIMS.NET/BIOGEN2019/ NO LATER THAN 11:59 P.M. ET ON JANUARY 19, 2027, OR IT MUST BE MAILED TO THE CLAIMS ADMINISTRATOR AT THE ADDRESS BELOW, POSTMARKED NO LATER THAN JANUARY 19, 2027:

Biogen Inc. Securities Litigation
c/o Strategic Claims Services
600 N. Jackson St., Ste. 205
P.O. Box 230
Media, PA 19063
Toll-Free: (866) 274-4004
Fax: (610) 565-7985
info@strategicclaims.net

A Claim Form received by the Claims Administrator shall be deemed to have been submitted when postmarked, if the postmark date is on or before January 19, 2027 and it is mailed first-class and addressed in accordance with the above instructions. In all other cases, a Claim Form shall be deemed to have been submitted when actually received by the Claims Administrator.

You should be aware that it will take a significant amount of time to process fully all of the Claim Forms and to administer the Settlement. This work will be completed as promptly as time permits, given the need to investigate and tabulate each Claim Form. Please notify the Claims Administrator of any change of address.

REMINDER CHECKLIST

- Please be sure to sign this Claim Form on page 6. If this Claim Form is submitted on behalf of joint Claimants, each Claimant must sign.

- Please remember to attach supporting documents. Do NOT send any stock certificates. Keep copies of everything you submit.

- Do NOT use highlighter on the Claim Form or any supporting documents.

- If you move or change your address, telephone number, or email address, please submit the new information to the Claims Administrator, as well as any other information that will assist us in contacting you. NOTE: Failure to submit updated information to the Claims Administrator may result in the Claims Administrator's inability to contact you regarding issues with your claim or to deliver payment to you.

Biogen Inc. Securities Litigation
c/o Strategic Claims Services
600 N. Jackson St., Ste. 205
Media, PA 19063

IMPORTANT LEGAL NOTICE – PLEASE FORWARD